<p>Boothbay Fund Management LLC 在最近向證券交易委員會的披露中表示，在第一季度減少了對 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - 免費報告) 的持股比例，降幅為 4.4%。該公司在此期間出售了 60,412 股後，持有生物技術公司 1,324,221 股股票。Boothbay Fund Management LLC 在最近一個季度末持有的 BioCryst Pharmaceuticals 的股份約佔 0.63%，價值 9,932,000 美元。</p>
<p>其他幾家對沖基金和機構投資者最近也對該公司的持倉進行了調整。安聯資產管理有限公司在第一季度將其在 BioCryst Pharmaceuticals 的股份增加了 9.6%。安聯資產管理有限公司目前持有 13,700 股生物技術公司的股票，價值 103,000 美元，此前在此期間又增持了 1,200 股。加拿大皇家銀行在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 2.4%。加拿大皇家銀行目前持有 63,463 股生物技術公司的股票，價值 476,000 美元，此前在此期間又增持了 1,458 股。SG Americas Securities LLC 在第一季度將其在 BioCryst Pharmaceuticals 的股份增加了 5.2%。SG Americas Securities LLC 目前持有 43,496 股生物技術公司的股票，價值 326,000 美元，此前在上個季度又增持了 2,146 股。威靈頓管理集團在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 2.6%。威靈頓管理集團目前持有 91,348 股生物技術公司的股票，價值 685,000 美元，此前在此期間又增持了 2,291 股。最後，Mariner LLC 在第四季度將其在 BioCryst Pharmaceuticals 的持倉增加了 32.1%。Mariner LLC 目前持有 13,258 股生物技術公司的股票，價值 100,000 美元，此前在上個季度又增持了 3,224 股。目前，85.88% 的股票由機構投資者持有。</p>
<h2>BioCryst Pharmaceuticals 價格表現</h2>
<p>NASDAQ:BCRX 週四開盤價為 8.29 美元。該公司的市值為 17.4 億美元，市盈率為 -46.05，市盈率增長比率為 1.89，貝塔值為 1.13。該股票的 50 日簡單移動平均線為 8.57 美元，200 日簡單移動平均線為 8.77 美元。BioCryst Pharmaceuticals, Inc. 的 12 個月最低價為 6.01 美元，最高價為 11.31 美元。</p>
<p>BioCryst Pharmaceuticals (NASDAQ:BCRX - 獲取免費報告) 最近於 8 月 4 日星期一發布了季度財報。該生物技術公司報告本季度每股收益為 0.15 美元，超出市場共識預期的 0.03 美元，超出幅度為 0.12 美元。該公司在本季度的收入為 1.6335 億美元，而市場共識預期為 1.4959 億美元。BioCryst Pharmaceuticals 本季度的收入同比增長 49.5%。在去年同期，該公司每股收益為 -0.06 美元。分析師平均預計 BioCryst Pharmaceuticals, Inc. 本財年將發佈 -0.36 美元的每股收益。</p>
<h2>BioCryst Pharmaceuticals 內部交易</h2>
<p>在其他 BioCryst Pharmaceuticals 的新聞中，董事 Theresa Heggie 於 8 月 13 日星期三出售了 70,000 股該股票。該股票的平均售價為 8.51 美元，總價值為 595,700.00 美元。交易完成後，該董事直接持有公司 65,352 股股票，估值約為 556,145.52 美元。這筆交易代表了他們持有股票的比例減少了 51.72%。該交易已在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。目前，5.10% 的股票由內部人士持有。</p>
<h2>華爾街分析師觀點</h2>
<p>BCRX 是多份研究報告的主題。巴克萊在 5 月 7 日的報告中將 BioCryst Pharmaceuticals 的目標價從 8.00 美元上調至 11.00 美元，並給予該股票 “持平” 評級。Wall Street Zen 在 7 月 26 日的研究報告中將 BioCryst Pharmaceuticals 的評級從 “買入” 上調至 “強力買入”。加拿大皇家銀行在 6 月 30 日的報告中重申了 “跑贏大盤” 評級，並對 BioCryst Pharmaceuticals 的股票設定了 13.00 美元的目標價。美國銀行在 7 月 1 日的報告中將 BioCryst Pharmaceuticals 的目標價從 13.00 美元上調至 15.00 美元，並給予該股票 “買入” 評級。最後，Wedbush 在 6 月 30 日的研究報告中將 BioCryst Pharmaceuticals 的目標價從 16.00 美元上調至 18.00 美元，並給予該公司 “跑贏大盤” 評級。九位投資分析師對該股票給予了 “買入” 評級，一位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，BioCryst Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 16.70 美元。</p>
<p><strong>閲讀我們對 BioCryst Pharmaceuticals 的最新分析</strong></p>
<h2>關於 BioCryst Pharmaceuticals</h2>
<p>(免費報告)</p>
<p>BioCryst Pharmaceuticals, Inc. 是一家生物技術公司，開發口服小分子和蛋白質治療藥物以治療罕見疾病。該公司銷售的藥物包括用於治療急性非複雜流感的靜脈注射藥物 peramivir，商品名為 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用於治療遺傳性血管性水腫的口服絲氨酸蛋白酶抑制劑 ORLADEYO。</p>
<h2>特色故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 BioCryst Pharmaceuticals</li>
<li>技術股解析：關於科技你需要知道的事</li>
<li>ETF 的迴歸：三隻可能持續表現優異的股票</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>開學購物達到 400 億美元：現在值得關注的三隻零售股票</li>
<li>現在值得購買的三隻沃倫·巴菲特股票</li>
<li>Alphabet 股票在躲避嚴厲的反壟斷措施後大幅上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 BioCryst 製藥嗎？</h2>
<p>在考慮 BioCryst 製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 BioCryst 製藥並不在名單上。</p>
<p>雖然 BioCryst 製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BioCryst制藥

<p>Boothbay Fund Management LLC 在第一季度減少了對 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 的持股比例，減持了 4.4%，出售了 60,412 股，剩餘持有 1,324,221 股，價值約 993 萬美元。其他機構投資者也調整了他們的持倉。BioCryst 的股票開盤價為 8.29 美元，市值為 17.4 億美元。該公司報告了同比 49.5% 的收入增長，季度每股收益為 0.15 美元，超出預期。分析師對該股票給予 “適度買入” 的評級，目標價格範圍為 8.00 美元至 18.00 美元</p>

<p>Boothbay Fund Management LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.4% during the 1st quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 1,324,221 shares of the biotechnology company's stock after selling 60,412 shares during the period. Boothbay Fund Management LLC owned about 0.63% of BioCryst Pharmaceuticals worth $9,932,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Boothbay Fund Management LLC 在最近向證券交易委員會的披露中表示，在第一季度減少了對 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - 免費報告) 的持股比例，降幅為 4.4%。該公司在此期間出售了 60,412 股後，持有生物技術公司 1,324,221 股股票。Boothbay Fund Management LLC 在最近一個季度末持有的 BioCryst Pharmaceuticals 的股份約佔 0.63%，價值 9,932,000 美元。</p>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Allianz Asset Management GmbH raised its stake in BioCryst Pharmaceuticals by 9.6% in the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 1,200 shares during the period. Royal Bank of Canada boosted its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after buying an additional 1,458 shares during the period. SG Americas Securities LLC grew its stake in BioCryst Pharmaceuticals by 5.2% in the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after buying an additional 2,146 shares during the last quarter. Wellington Management Group LLP raised its holdings in BioCryst Pharmaceuticals by 2.6% in the 1st quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company's stock valued at $685,000 after acquiring an additional 2,291 shares during the period. Finally, Mariner LLC lifted its position in BioCryst Pharmaceuticals by 32.1% during the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 3,224 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也對該公司的持倉進行了調整。安聯資產管理有限公司在第一季度將其在 BioCryst Pharmaceuticals 的股份增加了 9.6%。安聯資產管理有限公司目前持有 13,700 股生物技術公司的股票，價值 103,000 美元，此前在此期間又增持了 1,200 股。加拿大皇家銀行在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 2.4%。加拿大皇家銀行目前持有 63,463 股生物技術公司的股票，價值 476,000 美元，此前在此期間又增持了 1,458 股。SG Americas Securities LLC 在第一季度將其在 BioCryst Pharmaceuticals 的股份增加了 5.2%。SG Americas Securities LLC 目前持有 43,496 股生物技術公司的股票，價值 326,000 美元，此前在上個季度又增持了 2,146 股。威靈頓管理集團在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 2.6%。威靈頓管理集團目前持有 91,348 股生物技術公司的股票，價值 685,000 美元，此前在此期間又增持了 2,291 股。最後，Mariner LLC 在第四季度將其在 BioCryst Pharmaceuticals 的持倉增加了 32.1%。Mariner LLC 目前持有 13,258 股生物技術公司的股票，價值 100,000 美元，此前在上個季度又增持了 3,224 股。目前，85.88% 的股票由機構投資者持有。</p>
</div><h2>BioCryst Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>BioCryst Pharmaceuticals 價格表現</h2>
</div><p>NASDAQ:BCRX opened at $8.29 on Thursday. The firm has a market capitalization of $1.74 billion, a PE ratio of -46.05, a price-to-earnings-growth ratio of 1.89 and a beta of 1.13. The stock's 50-day simple moving average is $8.57 and its 200 day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.</p>
<div class="lb-trans"><p>NASDAQ:BCRX 週四開盤價為 8.29 美元。該公司的市值為 17.4 億美元，市盈率為 -46.05，市盈率增長比率為 1.89，貝塔值為 1.13。該股票的 50 日簡單移動平均線為 8.57 美元，200 日簡單移動平均線為 8.77 美元。BioCryst Pharmaceuticals, Inc. 的 12 個月最低價為 6.01 美元，最高價為 11.31 美元。</p>
</div><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - 獲取免費報告) 最近於 8 月 4 日星期一發布了季度財報。該生物技術公司報告本季度每股收益為 0.15 美元，超出市場共識預期的 0.03 美元，超出幅度為 0.12 美元。該公司在本季度的收入為 1.6335 億美元，而市場共識預期為 1.4959 億美元。BioCryst Pharmaceuticals 本季度的收入同比增長 49.5%。在去年同期，該公司每股收益為 -0.06 美元。分析師平均預計 BioCryst Pharmaceuticals, Inc. 本財年將發佈 -0.36 美元的每股收益。</p>
</div><h2>Insider Transactions at BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>BioCryst Pharmaceuticals 內部交易</h2>
</div><p>In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 5.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 BioCryst Pharmaceuticals 的新聞中，董事 Theresa Heggie 於 8 月 13 日星期三出售了 70,000 股該股票。該股票的平均售價為 8.51 美元，總價值為 595,700.00 美元。交易完成後，該董事直接持有公司 65,352 股股票，估值約為 556,145.52 美元。這筆交易代表了他們持有股票的比例減少了 51.72%。該交易已在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。目前，5.10% 的股票由內部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>BCRX has been the subject of several research reports. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, May 7th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, July 26th. Royal Bank Of Canada reissued an &#34;outperform&#34; rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, July 1st. Finally, Wedbush lifted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $16.70.</p>
<div class="lb-trans"><p>BCRX 是多份研究報告的主題。巴克萊在 5 月 7 日的報告中將 BioCryst Pharmaceuticals 的目標價從 8.00 美元上調至 11.00 美元，並給予該股票 “持平” 評級。Wall Street Zen 在 7 月 26 日的研究報告中將 BioCryst Pharmaceuticals 的評級從 “買入” 上調至 “強力買入”。加拿大皇家銀行在 6 月 30 日的報告中重申了 “跑贏大盤” 評級，並對 BioCryst Pharmaceuticals 的股票設定了 13.00 美元的目標價。美國銀行在 7 月 1 日的報告中將 BioCryst Pharmaceuticals 的目標價從 13.00 美元上調至 15.00 美元，並給予該股票 “買入” 評級。最後，Wedbush 在 6 月 30 日的研究報告中將 BioCryst Pharmaceuticals 的目標價從 16.00 美元上調至 18.00 美元，並給予該公司 “跑贏大盤” 評級。九位投資分析師對該股票給予了 “買入” 評級，一位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，BioCryst Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 16.70 美元。</p>
</div><p><strong>Read Our Latest Analysis on BioCryst Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 BioCryst Pharmaceuticals 的最新分析</strong></p>
</div><h2>About BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 BioCryst Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals, Inc. 是一家生物技術公司，開發口服小分子和蛋白質治療藥物以治療罕見疾病。該公司銷售的藥物包括用於治療急性非複雜流感的靜脈注射藥物 peramivir，商品名為 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用於治療遺傳性血管性水腫的口服絲氨酸蛋白酶抑制劑 ORLADEYO。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than BioCryst Pharmaceuticals</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Return of the ETFs: 3 Names That Could Keep Outperforming</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 BioCryst Pharmaceuticals</li>
<li>技術股解析：關於科技你需要知道的事</li>
<li>ETF 的迴歸：三隻可能持續表現優異的股票</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>開學購物達到 400 億美元：現在值得關注的三隻零售股票</li>
<li>現在值得購買的三隻沃倫·巴菲特股票</li>
<li>Alphabet 股票在躲避嚴厲的反壟斷措施後大幅上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 BioCryst 製藥嗎？</h2>
</div><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 BioCryst 製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 BioCryst 製藥並不在名單上。</p>
</div><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioCryst 製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Boothbay Fund Management LLC 出售了 60,412 股 BioCryst 製藥公司（股票代碼：BCRX）的股票